Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
5,149 people get NVS articles and Market Currents by email alert.
Get email alerts on NVS »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
Novartis Moving Forward In GenericsPeter Pham • Mon, Dec 3, 2012 -
-
AHA - 2 Hits And Several Misses With Novartis' SerelaxinEP Vantage • Wed, Nov 7, 2012 -
-
-
-
-
-
-
-
-
-
Novartis AG's CEO Discusses Q1 2012 Results - Earnings Call TranscriptTue, Apr 24, 2012 • 1 Comment
-
Novartis AG's CEO Discusses Q4 2011 Results - Earnings Call TranscriptWed, Jan 25, 2012
-
Novartis AG's CEO Discusses Q3 2011 Results - Earnings Call TranscriptTue, Oct 25, 2011
-
Novartis AG's CEO Discusses Q2 2011 Results - Earnings Call TranscriptTue, Jul 19, 2011
-
Novartis CEO Discusses Q4 2010 Results - Earnings Call TranscriptThu, Jan 27, 2011
-
Novartis 2009 Annual Conference Call TranscriptTue, Jan 26, 2010
-
Novartis AG Q3 2007 Earnings Call TranscriptThu, Oct 18, 2007 • 1 Comment
-
Novartis Q2 2007 Earnings Call TranscriptTue, Jul 17, 2007
-
at CNBC.com (Thu, 7:33AM)
-
at CNBC.com (Wed, 11:07AM)
-
at CNBC.com (May 10, 2013)
-
at Fox Business (Apr 26, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at MarketWatch.com (Apr 16, 2013)
-
at MarketWatch.com (Apr 15, 2013)
-
at CNBC.com (Apr 8, 2013)
-
at CNBC.com (Apr 3, 2013)
-
at MarketWatch.com (Apr 1, 2013)
-
at MarketWatch.com (Apr 1, 2013)
-
at Fox Business (Apr 1, 2013)
-
at MarketWatch.com (Apr 1, 2013)
-
at CNBC.com (Apr 1, 2013)
-
at CNBC.com (Apr 1, 2013)
-
at MarketWatch.com (Apr 1, 2013)
-
at CNBC.com (Feb 19, 2013)
-
at CNBC.com (Feb 1, 2013)
NVS vs. ETF Alternatives
Company Description
Currently, there's no company description for NVS.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, May 7, 4:02 PM Endo Health (ENDP +0.8%) is set to finish in the green today, despite posting a mixed Q1. Net earnings swung to a profit amid fewer write-downs and other items, as well as a modest revenue increase on strong generic sales growth. Generic sales +23% at $178M, while branded-pharmaceutical sales declined 2% to $358M. Lidoderm sales dropped 11%, mostly owing to its supply agreement with Actavis (ACT). Sales of Opana ER slumped 31% as sales continue to lag following a disruption early last year resulting from the closing of a Novartis (NVS) plant. Comment! [Healthcare, Earnings]
- Wednesday, April 24, 5:37 AM Novartis AG (NVS): Q1 EPS of $1.32 beats by $0.04. Revenue of $14B (+2% Y/Y) misses by $0.02B. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Wednesday, April 24, 12:05 AM Notable earnings before Wednesday’s open: ABB, ABX, ASH, ATI, AVY, BA, BYD, CFR, CKSW, COR, CP, CS, CVE, DPS, EDU, ELN, EMN, ERIC, F, FDML, GD, GLW, GRA, HCBK, HES, ICON, LAD, LL, LLY, LO, MDCO, MSI, MTH, NDAQ, NOC, NS, NVS, NYCB, OC, OCR, OSIS, PG, PLD, PX, RES, ROK, S, SO, SVU, TEL, TKR, TMO, TROW, TUP, USG, VLY, VMED, WAB, WHR, WLP, WM, WYN Comment! [Earnings]
- Tuesday, April 23, 5:30 PM Notable earnings before Wednesday’s open: ABB, ABX, ASH, ATI, AVY, BA, BYD, CFR, CKSW, COR, CP, CS, CVE, DPS, EDU, ELN, EMN, ERIC, F, FDML, GD, GLW, GRA, HCBK, HES, ICON, LAD, LL, LLY, LO, MDCO, MSI, MTH, NDAQ, NOC, NS, NVS, NYCB, OC, OCR, OSIS, PG, PLD, PX, RES, ROK, S, SO, SVU, TEL, TKR, TMO, TROW, TUP, USG, VLY, VMED, WAB, WHR, WLP, WM, WYN Comment! [Earnings]
- Wednesday, January 23, 4:06 AM More on Novartis (NVS) Q4: Chairman Daniel Vasella will resign and will be replaced by senior Bayer health-care executive Joerg Reinhardt, who was formerly COO at Novartis. Provides mid-term guidance for the first time, forecasting mid-single-digit percentage fall in core earnings this year; sales to be in line with 2012, excluding currency swings, although generic competition will eat into revenue by up to $3.5B. Sales growth to resume in 2014 and 2015. Comment! [Earnings, Healthcare]
- Wednesday, January 23, 4:04 AM More on Novartis (NVS) Q4: Adjusted profit +3% to $3.1B. Net profit +74% to $2.05B, below consensus of $2.38B. Last year was affected by writedowns. Pharmaceutical division sales flat at $8.3B, Diovan sales -25% to $992M after loss of patent protection. Shares +2.4% in Zurich. Comment! [Earnings, Healthcare]
- Wednesday, January 23, 3:42 AM Novartis AG (NVS): Q4 EPS of $1.27 may not be comparable to consensus of $1.31. Revenue of $14.8B (flat% Y/Y). The board intends to declare annual dividend of CHF2.25/share, 2.0% increase from prior dividend of CHF2.30. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Wednesday, January 23, 12:05 AM Notable earnings before Wednesday’s open: ABBV, ABT, APD, ATI, BHI, CHKP, COH, DGX, FNFG, GD, LCC, MCD, MSI, NVS, PX, RES, SAP, STJ, TEL, TXT, UTX, WLP Comment! [Earnings]
- Tuesday, January 22, 5:30 PM Notable earnings before Wednesday’s open: ABBV, ABT, APD, ATI, BHI, CHKP, COH, DGX, FNFG, GD, LCC, MCD, MSI, NVS, PX, RES, SAP, STJ, TEL, TXT, UTX, WLP Comment! [Earnings]
- Thursday, October 25, 2012, 5:22 AM More on Novartis (NVS) Q3: Net profit of $2.48B vs $2.49B. Earnings hurt by patent expirations, with Diovan (blood pressure) sales -32% to $969M after losing protection in September. Sandoz generic division revs -6%. New drugs helping to offset the patent cliff, and account for 29% of sales vs 25% a year ago. Consumer Health division sales -16% to $938M, due to manufacturing problems at Nebraska plant. Comment! [Earnings, Healthcare]
- Thursday, October 25, 2012, 4:18 AM Novartis (NVS): Q3 EPS of $1.34 in-line. Revenue of $13.8B (-7% Y/Y) misses by $450M. (PR) Comment! [Earnings, Healthcare]
- Thursday, October 25, 2012, 12:05 AM Notable earnings before Thursday’s open: ABB, AET, AUO, AVT, AZN, BEN, BG, BIIB, CAB, CCE, CELG, CL, CME, CMS, CNX, COP, CRR, CS, CVE, D, DBD, DDD, DNKN, EQT, GG, GTI, HERO, HOT, HSY, IMAX, IP, JBLU, JNS, LINE, LKQ, MCK, MJN, MO, MYL, NBL, NOV, NS, NVS, NXPI, NYT, O, ORI, OXY, PCAR, PCP, PDS, PG, PHM, POT, PTEN, RCL, ROC, RTN, RYN, S, SHW, SPG, SWI, TKR, TSM, TZOO, UA, UAL, VLY, VPHM, XEL, ZMH Comment! [Earnings]
- Wednesday, October 24, 2012, 5:30 PM Notable earnings before Thursday’s open: ABB, AET, AUO, AVT, AZN, BEN, BG, BIIB, CAB, CCE, CELG, CL, CME, CMS, CNX, COP, CRR, CS, CVE, D, DBD, DDD, DNKN, EQT, GG, GTI, HERO, HOT, HSY, IMAX, IP, JBLU, JNS, LINE, LKQ, MCK, MJN, MO, MYL, NBL, NOV, NS, NVS, NXPI, NYT, O, ORI, OXY, PCAR, PCP, PDS, PG, PHM, POT, PTEN, RCL, ROC, RTN, RYN, S, SHW, SPG, SWI, TKR, TSM, TZOO, UA, UAL, VLY, VPHM, XEL, ZMH 1 Comment [Earnings]
- Thursday, July 19, 2012, 8:37 AM More on Novartis (NVS +1.7%) Q2: net income flat at $2.7B, with revenues slipping partly because of patent expirations and the strength of the dollar. However, rising sales of new drugs, including Gilenya for multiple sclerosis and Afinitor for cancer, help offset the expirations. "Our pipeline is delivering," says CEO Joe Jimenez. Comment! [Healthcare, Earnings]
- Thursday, July 19, 2012, 6:18 AM Novartis (NVS): Q2 EPS of $1.38 beats by $0.05. Revenue of $14.3B (-4.1% Y/Y). (PR) Comment! [Earnings, Healthcare]
- Thursday, July 19, 2012, 12:05 AM Notable earnings before Thursday’s open: ADS, BAX, BBT, BX, CY, DGX, DHR, DO, FCS, FCX, FITB, GPC, HBAN, JCI, KEY, LUV, MS, NOK, NUE, NVS, PM, SHW, SWY, TCB, TRV, TSM, TXT, UNH, UNP, VZ Comment! [Earnings]
-
The Wall Street Transcript
Target Corporation ($TGT) and Novartis AG ($NVS) See a Decade of Dividend Growth- http://su.pr/2WdNba - View all 0 replies
-
- View all 0 replies
-
- View all 1 replies
-
-
Dividend Sheet
$PSEC $AT and $BTE are the best yielding ex-dividend stocks for tomorrow - http://stks.co/p3Xx - I like $NVS $TWC and $UNP - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Michael Bryant
"Novartis ($NVS) says trial results back Tasigna drug." Another buy and hold and reinvest the dividends. http://bit.ly/12i6N8w - View all 0 replies
-
- View all 0 replies
-
Mercy Jimenez
NVS flu vaccines temporarily halted in Italy; mayB NVS pps =more attractive http://reut.rs/Pr1bqh hat tip 2 Options Girl 4posting - View all 1 replies
-
driftking27: On calculating the possible divi income I receive £257, this means that I have only been taxed at 21% and NOT 35%.
LATEST REPLIES
-
- View all 1 replies
-
-
Mercy Jimenez
NVS flu vaccines temporarily halted in Italy; mayB NVS pps =more attractive http://reut.rs/Pr1bqh hat tip 2 Options Girl 4posting - View all 1 replies
-
driftking27: On calculating the possible divi income I receive £257, this means that I have only been taxed at 21% and NOT 35%.
-
Ryan Mallory
16 Defensive Stock Plays to Weather Market Uncertainty http://bit.ly/RVR8Ko AAPL ABT AMZN AZN MRK NVS PEP to name a few of them - View all 1 replies
-
driftking27: How do you see the strong CHf affecting there growth. I think that could be one hurdle that could hurt there sales. Plus NVS drops more...
-
Jacob Wolinsky
Johnson & Johnson: Why Value Investors Should be Looking http://bit.ly/M6zDRh $JNJ $NVS $AZN $BMY $PFE $GS - View all 1 replies
-
-
- View all 4 replies
-
daisymae: daisymae says coal will be in demand in China...oher than that Nat. Gas is our future
-
-
- View all 2 replies
-
-
Caiman Valores: YPF won't be paying a dividend, likely to be nationalized by Argentine government, find out more in my article http://bit.ly/ICs5GM
-
- View all 4 replies
-
shvartz: I bought at about 57. Adding the div to today's price gets about 58. And that is without tax, so for me there very little gain. -
Ocean Man: I bought some at 54.80 and sold at 57.40 pre-div, and I bought some at 55.80 which I sold today.
-
The Scientist
Still waiting for a response from AF from The Street on the licensing deals by APRI with ABT and NVS. Shows the value of NexACT technology - View all 1 replies
-
The Scientist: Huge multi-national biotechs do not do licensing deals with microcap biotech's unless they felt the technology is novel.
-
- View all 1 replies
-
-
- View all 14 replies
-
-
Ocean Man: Probably still worth a try at this price, only a few days left. I might buy some more, and will definitely buy any weakness.
-
- View all 3 replies
-
briandiplacido: Marked my shares up a buck @ 57.74 and someone took it premarket. Look for better re-entry now.
-
-
David Jackson
If you own dividend stocks like $INTC $JNJ $MSFT $NVS $DLN $DGS, note Vanguard's warning: http://seekingalpha.com/c/1fk0z - View all 13 replies
-
J. A. Saglimbeni: David, by the way a very good read by Vanguard...highly recommended -
Regarded Solutions: I use Fidelity, even like some funds, the business mod of these firms are geared for the bottom line. Not bad, just an opinion of mine
-
- View all 2 replies
-
Youngone91: ocean i bought kgc as well, for some reason kgc hesitated and i was able to pick it up at at 10.61 -
-
- View all 3 replies
-
-
-
Dividend Sheet
Best Healthcare Stock Picks For 2012: http://bit.ly/w32xHl + $MRK $NVS $STJ $TEVA $TMO $CELG $GILD - View all 2 replies
-
-
